UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-3916571 (State or other jurisdic ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) vTv Therapeutics Inc. For the fiscal year ended December 31, 2021 (Exact name of registrant as specified in its charter) Or Delaware 47-3916571 (State or other jurisdiction of incorporation or organization) 3980 Premier Dr, Suite 310 High Point, NC 27265 (Address of principal executive offices) (Zip Code) ☐ TRANSITION REPORT PURSU ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-3916571 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-3916571 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-3916571 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

For the quarterly period ended September 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-3916571 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) (Mark One) Delaware 47-3916571 (State or other jurisdict ...

[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) Covers financial statements, management's discussion, market risks, and internal controls for the period [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Details the company's Q1 2020 financial performance, including a significant revenue decline, increased net loss, and a widened stockholders' deficit [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Reports a decrease in total assets and cash, alongside a widened stockholders' deficit as of March 31, 2020 Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | March 31, 2020 (Unaudited) | December 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $406 | $1,777 | | Total current assets | $3,502 | $2,838 | | Total assets | $7,389 | $9,266 | | Total current liabilities | $11,970 | $13,381 | | Total liabilities | $17,014 | $18,106 | | Total stockholders' deficit | $(61,821) | $(49,023) | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Details Q1 2020 operations, showing sharp revenue drop and increased net loss from higher R&D expenses Condensed Consolidated Statements of Operations (in thousands, except per share data) | Metric | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Revenue | $8 | $921 | | Research and development | $4,204 | $2,822 | | General and administrative | $2,450 | $2,386 | | Operating loss | $(6,646) | $(4,287) | | Net loss attributable to vTv Therapeutics Inc. | $(4,724) | $(2,155) | | Net loss per share (basic and diluted) | $(0.11) | $(0.26) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Shows stable operating cash outflow, decreased financing cash inflow, and a net cash decrease for Q1 2020 Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | $(5,560) | $(5,450) | | Net cash provided by financing activities | $4,189 | $8,726 | | Net (decrease) increase in cash | $(1,371) | $3,276 | | Total cash, cash equivalents and restricted cash, end of period | $2,906 | $7,459 | [Notes to Unaudited Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) Provides critical details on accounting policies, a going concern warning, and subsequent financing events - Management has substantial doubt about the Company's ability to continue as a going concern, as current cash and available funds are projected to meet liquidity requirements only into **June 2020**[28](index=28&type=chunk) - On April 1, 2020, the company amended its Loan Agreement to extend maturity dates, provide for three months of interest-only payments, and temporarily eliminate the minimum cash balance requirement until **July 1, 2020**[107](index=107&type=chunk)[108](index=108&type=chunk)[109](index=109&type=chunk) - On April 24, 2020, the company entered into a sales agreement for a Controlled Equity Offering (ATM) to sell up to **$13.0 million** of its Class A common stock[111](index=111&type=chunk) - As of March 31, 2020, MacAndrews & Forbes Incorporated and its affiliates controlled approximately **84.4%** of the combined voting power of the company's outstanding common stock[86](index=86&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Covers clinical pipeline, COVID-19 impact, financial performance, and critical liquidity concerns - The company's pipeline is led by TTP399 for type 1 diabetes, which showed positive Phase 2 results, and azeliragon for mild Alzheimer's in patients with type 2 diabetes, currently in a Phase 2 study (Elevage Study)[114](index=114&type=chunk)[115](index=115&type=chunk) - The COVID-19 pandemic may delay the screening and enrollment for the Elevage Study, potentially impacting the timing of results, which are expected in the **first half of 2021**[115](index=115&type=chunk)[118](index=118&type=chunk) - The company has substantial doubt about its ability to continue as a going concern, with current cash and available funding projected to meet liquidity requirements only into **September 2020**[137](index=137&type=chunk)[153](index=153&type=chunk) Research and Development Expenses by Project (in thousands) | Project | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Azeliragon | $2,401 | $703 | | TTP399 | $400 | $600 | | Other projects | $70 | $191 | | Indirect R&D expense | $1,333 | $1,328 | | **Total R&D expense** | **$4,204** | **$2,822** | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=30&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Assesses interest rate risk from floating-rate debt and minimal risk from cash investments - The company is exposed to interest rate risk through its Loan Agreement, which bears a floating interest rate of **10.5%** plus the amount by which one-month LIBOR exceeds **0.5%**[160](index=160&type=chunk) - Market risk from the investment portfolio is considered minimal as it consists of cash and cash equivalents with short-term maturities[161](index=161&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Confirms effective disclosure controls and procedures as of March 31, 2020, with no material changes - The CEO and CFO concluded that as of March 31, 2020, the company's disclosure controls and procedures were effective[163](index=163&type=chunk) - No changes were made to the internal control over financial reporting during the most recent fiscal quarter that would have a material effect[166](index=166&type=chunk) [PART II – OTHER INFORMATION](index=31&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) Covers legal proceedings, updated risk factors, equity sales, and a list of filed exhibits [Item 1. Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) States that the company is not currently involved in any material legal proceedings - The company is not currently involved in any material legal proceedings[168](index=168&type=chunk) [Item 1A. Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) Highlights significant risks from COVID-19 to operations, clinical trials, and financial stability - The COVID-19 pandemic is identified as a significant risk that could negatively impact the global economy, disrupt supply chains, and create market volatility[170](index=170&type=chunk) - The pandemic could specifically affect FDA operations, leading to delays in meetings for planned clinical trials, and slow patient enrollment in ongoing trials like the Elevage study[174](index=174&type=chunk)[176](index=176&type=chunk) - COVID-19 may also hinder the ability of license partners to continue development, which could delay or prevent the achievement of milestones and associated payments to the company[177](index=177&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Reports no new unregistered equity sales in Q1 2020 and notes dividend payment restrictions - No unregistered sales of equity securities occurred in Q1 2020 that were not already disclosed[178](index=178&type=chunk) [Item 6. Exhibits](index=34&type=section&id=Item%206.%20Exhibits) Lists the various documents and certifications filed as exhibits with the Form 10-Q - Key exhibits filed include the Second Amendment to the Venture Loan and Security Agreement and certifications from the CEO and CFO[182](index=182&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 3980 Premier Dr, Suite 310 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...